Do analysts recommend RGC or RGNX?

REGENXBIO has a consensus target price of $23.82, suggesting a potential upside of 70.74%. Given REGENXBIO's stronger consensus rating and higher probable upside, analysts clearly believe REGENXBIO is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 REGENXBIO 1 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.75

Which has better valuation & earnings, RGC or RGNX?

Regencell Bioscience has higher earnings, but lower revenue than REGENXBIO. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Regencell Bioscience N/A N/A -$3.58M N/A N/A REGENXBIO $87.82M 8.21 -$193.88M -$5.60 N/A

Does the media prefer RGC or RGNX?

In the previous week, REGENXBIO had 7 more articles in the media than Regencell Bioscience. MarketBeat recorded 9 mentions for REGENXBIO and 2 mentions for Regencell Bioscience. REGENXBIO's average media sentiment score of 0.86 beat Regencell Bioscience's score of 0.58 indicating that REGENXBIO is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regencell Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive REGENXBIO 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer KLRA or RGNX?

In the previous week, REGENXBIO had 2 more articles in the media than Kailera Therapeutics. MarketBeat recorded 9 mentions for REGENXBIO and 7 mentions for Kailera Therapeutics. REGENXBIO's average media sentiment score of 0.86 beat Kailera Therapeutics' score of 0.43 indicating that REGENXBIO is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kailera Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral REGENXBIO 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer VERA or RGNX?

In the previous week, Vera Therapeutics had 27 more articles in the media than REGENXBIO. MarketBeat recorded 36 mentions for Vera Therapeutics and 9 mentions for REGENXBIO. REGENXBIO's average media sentiment score of 0.86 beat Vera Therapeutics' score of 0.58 indicating that REGENXBIO is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vera Therapeutics 12 Very Positive mention(s) 6 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive REGENXBIO 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is RGNX or IRON more profitable?

Disc Medicine has a net margin of 0.00% compared to REGENXBIO's net margin of -330.23%. Disc Medicine's return on equity of -36.94% beat REGENXBIO's return on equity. Company Net Margins Return on Equity Return on Assets REGENXBIO -330.23% -232.50% -61.02% Disc Medicine N/A -36.94% -33.88%

Does the media favor RGNX or IRON?

In the previous week, REGENXBIO had 2 more articles in the media than Disc Medicine. MarketBeat recorded 9 mentions for REGENXBIO and 7 mentions for Disc Medicine. REGENXBIO's average media sentiment score of 0.86 beat Disc Medicine's score of 0.10 indicating that REGENXBIO is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment REGENXBIO 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Disc Medicine 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer RGNX or MOR?

REGENXBIO currently has a consensus target price of $23.82, suggesting a potential upside of 70.74%. Given REGENXBIO's stronger consensus rating and higher probable upside, equities research analysts plainly believe REGENXBIO is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score REGENXBIO 1 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.75 MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation & earnings, RGNX or MOR?

REGENXBIO has higher earnings, but lower revenue than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio REGENXBIO $87.82M 8.21 -$193.88M -$5.60 N/A MorphoSys $238.28M 11.99 -$205.35M -$3.48 N/A

Is RGNX or MOR more profitable?

MorphoSys has a net margin of -226.79% compared to REGENXBIO's net margin of -330.23%. REGENXBIO's return on equity of -232.50% beat MorphoSys' return on equity. Company Net Margins Return on Equity Return on Assets REGENXBIO -330.23% -232.50% -61.02% MorphoSys -226.79% -694.31% -22.55%

REGENXBIO (RGNX) Competitors

$13.95 -1.70 (-10.86%)

Closing price 07/10/2026 04:00 PM Eastern

Extended Trading

$14.06 +0.11 (+0.82%)

As of 07/10/2026 07:56 PM Eastern

Compare

RGNX vs. RGC, KLRA, VERA, IRON, and MOR

Should you buy REGENXBIO stock or one of its competitors? MarketBeat compares REGENXBIO with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with REGENXBIO include Regencell Bioscience (RGC), Kailera Therapeutics (KLRA), Vera Therapeutics (VERA), Disc Medicine (IRON), and MorphoSys (MOR). These companies are all part of the "pharmaceutical products" industry.

How does REGENXBIO compare to Regencell Bioscience?

Regencell Bioscience (NASDAQ:RGC) and REGENXBIO (NASDAQ:RGNX) are both pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.

REGENXBIO has a consensus target price of $23.82, suggesting a potential upside of 70.74%. Given REGENXBIO's stronger consensus rating and higher probable upside, analysts clearly believe REGENXBIO is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
REGENXBIO	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

0.1% of Regencell Bioscience shares are held by institutional investors. Comparatively, 88.1% of REGENXBIO shares are held by institutional investors. 2.0% of Regencell Bioscience shares are held by insiders. Comparatively, 14.2% of REGENXBIO shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Regencell Bioscience has a beta of 1.84, indicating that its share price is 84% more volatile than the broader market. Comparatively, REGENXBIO has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market.

Regencell Bioscience has higher earnings, but lower revenue than REGENXBIO.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
REGENXBIO	$87.82M	8.21	-$193.88M	-$5.60	N/A

In the previous week, REGENXBIO had 7 more articles in the media than Regencell Bioscience. MarketBeat recorded 9 mentions for REGENXBIO and 2 mentions for Regencell Bioscience. REGENXBIO's average media sentiment score of 0.86 beat Regencell Bioscience's score of 0.58 indicating that REGENXBIO is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regencell Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
REGENXBIO	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Regencell Bioscience has a net margin of 0.00% compared to REGENXBIO's net margin of -330.23%. Regencell Bioscience's return on equity of 0.00% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
REGENXBIO	-330.23%	-232.50%	-61.02%

Summary

REGENXBIO beats Regencell Bioscience on 8 of the 13 factors compared between the two stocks.

How does REGENXBIO compare to Kailera Therapeutics?

Kailera Therapeutics (NASDAQ:KLRA) and REGENXBIO (NASDAQ:RGNX) are both pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

88.1% of REGENXBIO shares are held by institutional investors. 14.2% of REGENXBIO shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Kailera Therapeutics has higher earnings, but lower revenue than REGENXBIO. REGENXBIO is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kailera Therapeutics	N/A	N/A	N/A	-$3.65 thousand	N/A
REGENXBIO	$87.82M	8.21	-$193.88M	-$5.60	N/A

Kailera Therapeutics currently has a consensus target price of $42.75, suggesting a potential upside of 106.72%. REGENXBIO has a consensus target price of $23.82, suggesting a potential upside of 70.74%. Given Kailera Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Kailera Therapeutics is more favorable than REGENXBIO.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kailera Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00
REGENXBIO	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, REGENXBIO had 2 more articles in the media than Kailera Therapeutics. MarketBeat recorded 9 mentions for REGENXBIO and 7 mentions for Kailera Therapeutics. REGENXBIO's average media sentiment score of 0.86 beat Kailera Therapeutics' score of 0.43 indicating that REGENXBIO is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kailera Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
REGENXBIO	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kailera Therapeutics has a net margin of 0.00% compared to REGENXBIO's net margin of -330.23%. Kailera Therapeutics' return on equity of 0.00% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kailera Therapeutics	N/A	N/A	N/A
REGENXBIO	-330.23%	-232.50%	-61.02%

Summary

Kailera Therapeutics and REGENXBIO tied by winning 7 of the 14 factors compared between the two stocks.

How does REGENXBIO compare to Vera Therapeutics?

Vera Therapeutics (NASDAQ:VERA) and REGENXBIO (NASDAQ:RGNX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, risk, profitability, valuation and earnings.

Vera Therapeutics has a net margin of 0.00% compared to REGENXBIO's net margin of -330.23%. Vera Therapeutics' return on equity of -74.86% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vera Therapeutics	N/A	-74.86%	-60.18%
REGENXBIO	-330.23%	-232.50%	-61.02%

Vera Therapeutics presently has a consensus target price of $84.58, suggesting a potential upside of 101.39%. REGENXBIO has a consensus target price of $23.82, suggesting a potential upside of 70.74%. Given Vera Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Vera Therapeutics is more favorable than REGENXBIO.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77
REGENXBIO	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

99.2% of Vera Therapeutics shares are owned by institutional investors. Comparatively, 88.1% of REGENXBIO shares are owned by institutional investors. 15.9% of Vera Therapeutics shares are owned by company insiders. Comparatively, 14.2% of REGENXBIO shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Vera Therapeutics has a beta of 0.92, meaning that its stock price is 8% less volatile than the broader market. Comparatively, REGENXBIO has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market.

REGENXBIO has higher revenue and earnings than Vera Therapeutics. Vera Therapeutics is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.54	N/A
REGENXBIO	$87.82M	8.21	-$193.88M	-$5.60	N/A

In the previous week, Vera Therapeutics had 27 more articles in the media than REGENXBIO. MarketBeat recorded 36 mentions for Vera Therapeutics and 9 mentions for REGENXBIO. REGENXBIO's average media sentiment score of 0.86 beat Vera Therapeutics' score of 0.58 indicating that REGENXBIO is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vera Therapeutics	12 Very Positive mention(s)	6 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
REGENXBIO	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Vera Therapeutics beats REGENXBIO on 11 of the 15 factors compared between the two stocks.

How does REGENXBIO compare to Disc Medicine?

REGENXBIO (NASDAQ:RGNX) and Disc Medicine (NASDAQ:IRON) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation.

In the previous week, REGENXBIO had 2 more articles in the media than Disc Medicine. MarketBeat recorded 9 mentions for REGENXBIO and 7 mentions for Disc Medicine. REGENXBIO's average media sentiment score of 0.86 beat Disc Medicine's score of 0.10 indicating that REGENXBIO is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
REGENXBIO	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Disc Medicine	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

REGENXBIO has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market. Comparatively, Disc Medicine has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market.

REGENXBIO presently has a consensus target price of $23.82, indicating a potential upside of 70.74%. Disc Medicine has a consensus target price of $104.44, indicating a potential upside of 36.37%. Given REGENXBIO's stronger consensus rating and higher probable upside, equities analysts clearly believe REGENXBIO is more favorable than Disc Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
REGENXBIO	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Disc Medicine has a net margin of 0.00% compared to REGENXBIO's net margin of -330.23%. Disc Medicine's return on equity of -36.94% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
REGENXBIO	-330.23%	-232.50%	-61.02%
Disc Medicine	N/A	-36.94%	-33.88%

REGENXBIO has higher revenue and earnings than Disc Medicine. Disc Medicine is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
REGENXBIO	$87.82M	8.21	-$193.88M	-$5.60	N/A
Disc Medicine	N/A	N/A	-$212.18M	-$6.62	N/A

88.1% of REGENXBIO shares are held by institutional investors. Comparatively, 83.7% of Disc Medicine shares are held by institutional investors. 14.2% of REGENXBIO shares are held by company insiders. Comparatively, 3.8% of Disc Medicine shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

REGENXBIO beats Disc Medicine on 11 of the 15 factors compared between the two stocks.

How does REGENXBIO compare to MorphoSys?

REGENXBIO (NASDAQ:RGNX) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, media sentiment, dividends and profitability.

88.1% of REGENXBIO shares are owned by institutional investors. Comparatively, 18.4% of MorphoSys shares are owned by institutional investors. 14.2% of REGENXBIO shares are owned by company insiders. Comparatively, 0.1% of MorphoSys shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

REGENXBIO currently has a consensus target price of $23.82, suggesting a potential upside of 70.74%. Given REGENXBIO's stronger consensus rating and higher probable upside, equities research analysts plainly believe REGENXBIO is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
REGENXBIO	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, REGENXBIO had 9 more articles in the media than MorphoSys. MarketBeat recorded 9 mentions for REGENXBIO and 0 mentions for MorphoSys. REGENXBIO's average media sentiment score of 0.86 beat MorphoSys' score of 0.00 indicating that REGENXBIO is being referred to more favorably in the media.

Company	Overall Sentiment
REGENXBIO	Positive
MorphoSys	Neutral

REGENXBIO has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market. Comparatively, MorphoSys has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market.

MorphoSys has a net margin of -226.79% compared to REGENXBIO's net margin of -330.23%. REGENXBIO's return on equity of -232.50% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
REGENXBIO	-330.23%	-232.50%	-61.02%
MorphoSys	-226.79%	-694.31%	-22.55%

REGENXBIO has higher earnings, but lower revenue than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
REGENXBIO	$87.82M	8.21	-$193.88M	-$5.60	N/A
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A

Summary

REGENXBIO beats MorphoSys on 10 of the 16 factors compared between the two stocks.

Get REGENXBIO News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RGNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RGNX vs. The Competition

Export

Metric	REGENXBIO	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$721.19M	$3.71B	$7.09B	$12.66B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-2.49	21.64	27.42	24.53
Price / Sales	8.21	341.29	534.60	97.42
Price / Cash	N/A	143.33	48.47	60.03
Price / Book	6.87	8.41	10.88	6.38
Net Income	-$193.88M	$23.85M	$3.59B	$331.87M
7 Day Performance	5.05%	-0.75%	-0.26%	0.35%
1 Month Performance	109.46%	8.68%	4.55%	0.57%
1 Year Performance	60.71%	55.85%	29.86%	22.26%

REGENXBIO Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RGNX REGENXBIO	3.6483 of 5 stars	$13.95 -10.9%	$23.82 +70.7%	+60.7%	$721.19M	$87.82M	N/A	370	News Coverage
RGC Regencell Bioscience	0.2259 of 5 stars	$6.11 -4.1%	N/A	-60.1%	$3.05B	N/A	N/A	10
KLRA Kailera Therapeutics	4.1833 of 5 stars	$22.83 +3.8%	$42.75 +87.3%	N/A	$2.96B	N/A	N/A	145	News Coverage Short Interest Increase
VERA Vera Therapeutics	3.5076 of 5 stars	$40.75 -1.1%	$78.00 +91.4%	+76.3%	$2.93B	N/A	N/A	40	Trending News Analyst Forecast Insider Trade Analyst Revision
IRON Disc Medicine	2.2927 of 5 stars	$75.25 -1.3%	$104.44 +38.8%	+34.6%	$2.87B	N/A	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RGNX) was last updated on 7/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

REGENXBIO (RGNX) Competitors

RGNX vs. RGC, KLRA, VERA, IRON, and MOR

How does REGENXBIO compare to Regencell Bioscience?

Summary

How does REGENXBIO compare to Kailera Therapeutics?

Summary

How does REGENXBIO compare to Vera Therapeutics?

Summary

How does REGENXBIO compare to Disc Medicine?

Summary

How does REGENXBIO compare to MorphoSys?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGNX vs. The Competition

REGENXBIO Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

REGENXBIO (RGNX) Competitors

RGNX vs. RGC, KLRA, VERA, IRON, and MOR

How does REGENXBIO compare to Regencell Bioscience?

Do analysts recommend RGC or RGNX?

Do insiders and institutionals hold more shares of RGC or RGNX?

Which has more volatility & risk, RGC or RGNX?

Which has better valuation & earnings, RGC or RGNX?

Does the media prefer RGC or RGNX?

Is RGC or RGNX more profitable?

Summary

How does REGENXBIO compare to Kailera Therapeutics?

Do institutionals and insiders hold more shares of KLRA or RGNX?

Which has preferable earnings & valuation, KLRA or RGNX?

Do analysts recommend KLRA or RGNX?

Does the media prefer KLRA or RGNX?

Is KLRA or RGNX more profitable?

Summary

How does REGENXBIO compare to Vera Therapeutics?

Is VERA or RGNX more profitable?

Do analysts prefer VERA or RGNX?

Do institutionals & insiders have more ownership in VERA or RGNX?

Which has more risk and volatility, VERA or RGNX?

Which has higher earnings & valuation, VERA or RGNX?

Does the media prefer VERA or RGNX?

Summary

How does REGENXBIO compare to Disc Medicine?

Does the media favor RGNX or IRON?

Which has more risk & volatility, RGNX or IRON?

Do analysts recommend RGNX or IRON?

Is RGNX or IRON more profitable?

Which has preferable earnings and valuation, RGNX or IRON?

Do insiders & institutionals believe in RGNX or IRON?

Summary

How does REGENXBIO compare to MorphoSys?

Do insiders and institutionals have more ownership in RGNX or MOR?

Do analysts prefer RGNX or MOR?

Does the media favor RGNX or MOR?

Which has more risk and volatility, RGNX or MOR?

Is RGNX or MOR more profitable?

Which has better valuation & earnings, RGNX or MOR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGNX vs. The Competition

REGENXBIO Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools